Friday, October 18, 2019 - 16:00

INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq Global Select Market: IPHA) (“Innate” or the “Company”), a French biotechnology company focused on discovering, developing and commercializing first-in-class therapeutic antibodies designed to harness the immune system for the treatment of oncology indications with significant unmet medical need, today announced that the underwriters of its global offering of an aggregate of 12,500,000 new ordinary shares, comprising an offer of 8,047,227 ordinary shares in the form of American Depositary Shares (“ADSs”), each representing one ordinary share, and a concurrent private placement of 4,452,773 ordinary shares in Europe (including France) and other countries outside of the United States (the “Global Offering”), have exercised in full their option to purchase up to 1,875,000 additional ADSs.  The additional ADSs will be delivered concurrently with the closing of the Global Offering.

As a result, the total number of ordinary shares and ADSs issued in the Global Offering amounts to 14,375,000 ordinary shares, including 9,922,227 in the form of ADSs, bringing the gross proceeds of the Global Offering to approximately $79.1 million (€71.4 million)*.

Citigroup Global Markets Inc., acting as the stabilizing agent on its own behalf and on behalf of the other underwriters, reported that no stabilization activities had been carried out.  The period during which stabilization activities could be carried out is now closed.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.



*Based on an exchange rate of €1 = $1.1065 on October 16, 2019

PR in English111.77 KB
CP en français110.2 KB